Biofrontera Inc (BFRI)

Currency in USD
0.9637
+0.0880(+10.05%)
Closed·
0.9640+0.0003(+0.03%)
·
BFRI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
BFRI is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.88100.9699
52 wk Range
0.53602.2200
Key Statistics
Prev. Close
0.8757
Open
0.89
Day's Range
0.881-0.9699
52 wk Range
0.536-2.22
Volume
67.84K
Average Volume (3m)
162.07K
1-Year Change
-18.33%
Book Value / Share
-0.49
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BFRI Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.5000
Upside
+574.48%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Biofrontera Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Biofrontera Inc Company Profile

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Employees
93

Biofrontera Inc Earnings Call Summary for Q2/2025

  • Q2 2025 revenue up 15.4% YoY to $9M, driven by 9.5% increase in Ameluz sales volume and 5% price hike
  • Net loss of $5.3M reported; cash reserves at $7.2M as of June 30, 2025
  • Trial data for acne and peripheral actinic keratosis expected in Q4 2025; FDA application for basal cell carcinoma treatment planned
  • CEO highlights record-breaking results, customer segmentation strategy, and lamp placements as growth indicator
  • No price increases planned for 2025; focus on enhancing sales team efficiency and data analysis
Last Updated: 14/08/2025, 15:52
Read Full Transcript

Compare BFRI to Peers and Sector

Metrics to compare
BFRI
Peers
Sector
Relationship
P/E Ratio
−0.6x−1.5x−0.6x
PEG Ratio
−0.010.120.00
Price/Book
−2.2x1.6x2.6x
Price / LTM Sales
0.3x1.7x3.3x
Upside (Analyst Target)
-110.8%38.0%
Fair Value Upside
Unlock10.6%4.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 6.5000
(+574.48% Upside)

Earnings

Latest Release
Aug 13, 2025
EPS / Forecast
-0.57 / -0.57
Revenue / Forecast
9.03M / --
EPS Revisions
Last 90 days

BFRI Income Statement

People Also Watch

2.170
VOR
0.00%
3.3800
SNGX
+0.60%
0.130
WINT
-5.11%
2.41
INMB
+2.55%
7.09
FDMT
+3.50%

FAQ

What Stock Exchange Does Biofrontera Trade On?

Biofrontera is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Biofrontera?

The stock symbol for Biofrontera is "BFRI."

What Is the Biofrontera Market Cap?

As of today, Biofrontera market cap is 9.92M.

What Is Biofrontera's Earnings Per Share (TTM)?

The Biofrontera EPS (TTM) is -2.10.

From a Technical Analysis Perspective, Is BFRI a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Biofrontera Stock Split?

Biofrontera has split 1 times.

How Many Employees Does Biofrontera Have?

Biofrontera has 93 employees.

What is the current trading status of Biofrontera (BFRI)?

As of 24 Aug 2025, Biofrontera (BFRI) is trading at a price of 0.96, with a previous close of 0.88. The stock has fluctuated within a day range of 0.88 to 0.97, while its 52-week range spans from 0.54 to 2.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.